Medexus Pharmaceuticals has obtained exclusive Canadian rights to UM171 Cell Therapy (Zemcelpro®), a novel stem cell transplant product conditionally approved in Europe for treating blood cancers. The therapy, developed in Canada, is expected to launch commercially in Canada by 2028 or later, pending Health Canada approval. This deal strengthens Medexus's hemato-oncology portfolio and aims to address significant patient needs in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Medexus plans to submit for Canadian regulatory approval soon and may offer access through special programs before full approval.
Crédit Agricole S.A. declared a total of 3,025,902,350 voting rights as of July 31, 2026. The number of exercisable voting rights, accounting for shares without voting rights such as treasury shares, stands at 3,025,634,720. This declaration is part ...
The District Court of The Hague granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., stopping the sale of an unapproved compounded semaglutide nasal spray that infringes Novo Nordisk's patent. The court ruling protects...
SERES Group, marking its 40th anniversary, emphasizes ESG as a core strategy for global growth and sustainability. The company aims for carbon peak by 2030 and carbon neutrality by 2045, supported by a strong governance framework and innovative manuf...
Niber Technologies, founded by Korean brothers and based in Singapore, has developed PFAS-free electrospun nanofiber membranes to address tightening global regulations on harmful PFAS chemicals. Their membranes maintain high waterproof and breathable...
As back-to-school routines increase stress for 83% of parents, Raddish Kids provides monthly cooking and baking subscription boxes designed for children ages 4 to 14+. These kits encourage family bonding through shared meal preparation, helping kids ...
